Our data show that SIRT6 reduces hepatic FFA, FC and p53 levels and apoptosis, partially explaining how hepatocyte SIRT6 inhibits NASH development. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatohepatitis.